Topic Listing for SciClone Pharmaceuticals

Access Sciclone Pharmaceuticals Inc Stockholder Account Online Via Account Debtor Defined Code Such Additions Term Hereafter
Accounting Guidance Accounting Other Terms
Accounting Stock-based Compensation Accounts Receivable
Accrued Expenses Actions Not Taken Sciclone
Actions Not Taken Sigma Tau Group Actions Permitted Taken Sigma Tau Group
Actions Required Taken Sciclone Actions Required Taken Sigma-tau Group
Actions Sigma-tau Group Actions Taken Sciclone Implement Settlement Agreement
Additional Clinical Trials Required Successful Commercialization Zadaxin Results Administration
Adopted 2008 Adopted Current
Advertising Expenses Affirmative Covenants
Aggregate Compensation Aggregated Option Exercises Year-end Values
Agreement Amendment
Amendment Form 10-k Amendment License Agreement
Amendment Termination Plan Amendments
Amendments Articles Incorporation Bylaws Change Analytical Methods
Annual Cash Incentives Anti-takeover Provisions Charter Documents Delaware Law Make Acquisition
Arbitration Asia Europe
Assignment Purchase Agreement Assumed Liabilities
Auction Rate Securities Rights Offer Auditing
Available Information Bank
Base Salary Basis Presentation
Bead Bead Liver Cancer
Because Chinas Tiered Method Importing Distributing Finished Pharmaceutical Beneficial Ownership Reporting Compliance
Bio Ceo Investor Conference Board Directors Stockholders Sciclone Pharmaceuticals Inc
Board Meetings Committees Broadening Product Portfolio
Broadening Sciclone Chinas Product Portfolio Broadening Sciclones International Product Portfolio
Broker Non-votes Building Leading International Pharmaceutical Business
Business Operations Especially Subject Risks Earthquakes Other Natural Business Operations Subject Risks Being Based Particular Locations
Cannot Predict Safety Profile Thymalfasin Rp101 Bead Ondansetron Cannot Predict Safety Profile Thymalfasin Rp101 Scv-07 Used
Cannot Predict Safety Profile Zadaxin Rp101 Scv-07 Used Cannot Predict Safety Profile Zadaxin Used Combination Other
Capital Stock Cash Compensation
Cash Equivalents Investments Cash Investments Subject Certain Risks Materially Adversely Affect
Ceo Agreements Ceo Compensation
Certain Definitions Used Change Control Agreements Certain Relationships Related Transactions
Change Control Change Control Termination Benefits
Changes Chinas Political Social Economic Environment Affect Financial Changes Internal Control Over Financial Reporting
Changes Internal Controls Chief Financial Officer Secretary
China Pharmaceutical Market Chinese Pharmaceutical Market
Choice Law Venue Jury Trial Waiver Judicial Reference Code Ethics
Collaborative Agreements Collaborative Agreements Related Party Transactions
Collateral Description Commercialization Some Products Depends Collaborations Others Collaborators Not
Commitments Contingencies Committee Charters Other Corporate Governance Materials
Common Stock Warrants Communications Stockholders Directors
Compensation Committee Interlocks Insider Participation Compensation Committee Report
Compensation Committee Report Executive Compensation Directors
Compensation Philosophy Compensation Policy
Compensation Process Role Management Competition
Compliance 409a Compliance Certificate
Compliance Securities Law Comprehensive Income
Comprehensive Income Loss Comprehensive Loss
Comprehensive Loss Income Concentration Credit Risk
Condensed Consolidated Statements Operations Conditions Loans
Confidential Provisions Redacted Confidential Treatment Request Edited Copy
Confidential Treatment Request Redacted Copy Confidentiality
Consent Independent Registered Public Accounting Firm Consent Pharmaceutical Research Associates Inc Assignment Sciclone Certain
Consideration Contractual Obligations
Controls Procedures Convertible Notes Payable
Corporate Contact Corporate Milestones
Corporation Cost Product Sales Gross Margin
Covenant Default Creation Security Interest
Credit Insurance Policy Lapses Cancelled Invalid Banks Rights Credit Insurance Policy Lapses Cancelled Invalid Stylemargin-top18pxmargin-bottom0px Text-indent4
Critical Accounting Estimates Assumptions Critical Accounting Policies
Critical Accounting Policies Estimates Deferred Revenue Amounts Received Invoiced Advance Performance Contracts
Definitions Definitions Construction
Delivery Acceptance Departure Directors Certain Officers Election Appointment Compensatory
Depend International Sales Global Conditions Negatively Affect Operating Description 2008 Executive Incentive Plan
Developing Products European Markets Development Plan
Difficulty Recruiting Patients Clinical Trials Higher Anticipated Patient Director Attendance Annual Meetings
Director Compensation Director Independence
Director Nominations Director Qualifications
Directorships Disclosure Controls Procedures
Dividends Ecitals
Effect Change Control Election Nominees Named Above
Electronic Delivery Stockholder Communications Elements Compensation Program Each Element Chosen
Elements Sciclones Compensation Program Eligibility
Eligibility Participation Award Limitations Employee Stock Purchase Plan
Employees Employment Contracts Termination Change-in-control Arrangements
Engage Acquisitions Successfully Integrate Acquired Products Companies Order Equity Compensation
Equity Compensation Plan Information Established Business China
Estimates Evaluation Disclosure Controls Procedures
Events Default Exact Name Registrant Specified Charter
Exchange Act 1934 Amendment Executive Officers
Executive Officers Registrant Executive Sessions
Exhibits Expiration Termination Settlement Agreement
Fail Maintain Effective System Internal Controls Not Able Fail Protect Products Technologies Trade Secrets Not Able
Fair Value Financial Instruments Fair Value Measurements
Financial Covenants Financial Outlook 2009
Financial Results Financial Statements Exhibits
Financial Statements Reports Certificates Forcast Purchase Supply
Force Majeure Foreign Currency Translation
Form 10-k Form 10-q
Former Name Address Changed Since Last Report Forward-looking Statements
Foster City 8211 2008 Friedhelm Blobel Phd
Full Guidance Increased Revenues Earnings Full Revenues Eps End Cash Guidance Increased
Gary Titus General
General Administrative General Administrative Expenses
General Definitions General Provisions
General Release Claims General Release Not Extend Claims Creditor Know Suspect
Government Compliance Grant License Option
Grants Plan-based Awards Greement
Guarantor Hans Schmid
Hcv Higher Anticipated Patient Drop Out Rates Clinical Trials
History Operating Losses Accumulated Deficit Expect Continue Incur History Operating Losses Accumulated Deficit Expect Incur Near
However Not Guarantee Particular Tax Effect Income Provided Identifying Evaluating Candidates Nomination Director
Ilicon Alley Ank Impairment Intangible Assets
Important Information Solicitation Participants Legend Including Whistle Blowing Case Violations Policies
Income Taxes Incoming Control Defects
Increase Full Guidance Revenues Earnings Indebtedness Management
Indemnification Indemnification Directors Officers
Indemnification Limitations Liability Indemnity Agreement
Independent Compensation Consultants Peer Group Selection Benchmarking Index
Index Consolidated Financial Statements Index Exhibits
Instruction Withhold Authority Vote Individual Nominee Strike Line Intangible Assets
Intellectual Property Interest Investment Income
Interest Investment Income Expense Interest Investment Income Other Expense
International Sales Marketing Internet Telephone Vote Authorizes Named Proxies Shares Same
Inventories Investments Subject Certain Risks Materially Adversely Affect Overall
Involved Intellectual Property Claims Litigation Proceedings Divert Resources Israel Rios
Issue Full 2008 Financial Results Ivan Hui
Jon Saxe Chairman Board Directors Leases
Legal Proceedings Letters Credit Sublimit
Liability Indemnification License Agreement
License Royalty Obligations Limitation Liability
Limitations Effectiveness Controls Limitations Effectiveness Internal Controls
Limited Sales Marketing Distribution Capabilities Adversely Affect Ability Limited Sales Marketing Distribution Capabilities Outside China Adversely
Line-of-credit Liquidity Capital Resources
Liver Cancer Loan Security Agreement
Loan Terms Payment Lone Harmaceuticals
Lone Harmaceuticals Nternational Lone Harmaceuticals Nternational Hina Olding
Long-term Cash Incentives Long-term Equity Incentives
Long-term Liabilities Lose Key Personnel Unable Attract Retain Additional Highly
Lose Market Share Otherwise Fail Compete Effectively Intensely Malignant Melanoma
Managements Annual Report Internal Control Over Financial Reporting Manufacture Standards
Manufacturing Manufacturing Supply Agreement
Marked Signed Returned Proxy Card Marketable Securities
Master Production Control Record Batch Records Material Modification Rights Security Holders
Mendment Hange Ontrol Greement Mendment Mployment Greement
Miscellaneous Miscellaneous Provisions
Mutual Cooperation Corrective Roceedings Name Person Filing Proxy Statement Other Registrant
Need Obtain Additional Capital Support Long-term Product Development Need Obtain Additional Funding Support Long-term Product Development
Negative Covenants Net Income Loss Per Share
Net Loss Income Per Share Net Loss Per Share
New Accounting Pronouncements Impact Financial Position Results Operations New Legislation Impact Financial Position Results Operations
Nominees Non-gaap Financial Measures
Nondisclosure Obligations Not Able Establish Maintain Adequate Manufacturing Relationships Development
Not Able Proceed Filing Regulatory Approval Japan Dispute Not Able Successfully Develop Commercialize Products
Not Able Successfully Develop Commercialize Products Consider Strategic Not Applicable
Not Obtain Regulatory Approval Thymalfasin Rp101 Intended Indications Not Obtain Regulatory Approval Thymalfasin Rp101 Scv-07 Bead
Not Obtain Regulatory Approval Thymalfasin Rp101 Scv-07 Intended Not Obtain Regulatory Approval Thymalfasin Rp101 Scv-07 Ondansetron
Not Obtain Regulatory Approval Zadaxin Intended Indications Evaluating Not Yet Adopted
Notes Condensed Consolidated Financial Statements Notice Annual Meeting Stockholders
Notices Now Access Sciclone Pharmaceuticals Inc Account Online
Objectives Compensation Program Off-balance Sheet Arrangements
Officers Officers Certificate
Olding Operating Accounts
Option Exercises Stock Vested Last Option Grants 2005
Orders Supply Other Accrued Expenses
Other Assets Other Expense Income
Other Income Other Income Expense
Other Long-term Liabilities Other Matters
Other Transactions Policy Otice Nnual Eeting Tockholders
Outstanding Equity Awards Year-end Overview
Pancreatic Cancer Part
Part Other Information Patents
Payment Interest Credit Extensions Payment Past Supply
Payments Pegylated Zadaxin
Pension Benefits Nonqualified Deferred Compensation Plans Performance Graph
Phase Hcv Trial Protocol Phase Hepatitis Trial Results
Phase Interim Blinded Etr Phase Interim Blinded Svr
Phase Pancreatic Cancer Trial Protocol Phase Study Data
Phase Trial Rp101 Late-stage Pancreatic Cancer Phase Triple Therapy Trial Protocol
Pipeline Updates Plan
Post Closing Covenants Buyout Potential Payments Termination Change-in-control
Power Attorney Pre-existing Related Party Disclosure
Preclinical Data Prepaid Expenses Other Current Assets
Presentation President Chief Executive Officer
Press Release Dated 2009 Signature Price Adjustment Termination
Prices Payment Principal Accountant Fees
Principal Financial Officer Accounting Product Specification Licensed
Production Source Property Equipment
Proprietary Information Restrictions Proprietary Rights
Provision Income Tax Public Announcement
Purchase Obligations Quantitative Qualitative Disclosures Market Risk
Reaffirmation Unconditional Secured Guaranty Recent Accounting Pronouncement
Recent Accounting Pronouncements Recent Pipeline Updates
Recently Issued Accounting Pronouncement Recently Issued Accounting Pronouncements
Recitals Reclassification
Reclassifications Recommendation Board Directors
Recurrence Sars Outbreak Different Contagious Disease Such Avian Recurrence Severe Acute Respiratory Syndrome Sars Outbreak Different
Regarding Forward-looking Statements Regulatory Approval Necessary Permit Market Bead China Unable
Related Party Transactions Release
Rely Parties Corporate Collaborators Conduct Clinical Trials Not Rely Parties Development Products Inability Reliably Timely Cost-effectively
Rely Parties Supply Clinical Trial Commercial Products Deficiencies Rely Third-party Clinical Investigators Conduct Trials Result Encounter
Remainder Page Intentionally Left Blank Remedies
Reoccurrence Severe Acute Respiratory Syndrome Sars Outbreak Different Report Audit Committee
Report Independent Registered Public Accounting Firm Reports Records
Representations Warranties Representations Warranties Buyer
Representations Warranties Seller Required Vote
Research Development Research Development Expenses
Reserved Shares Restricted Stock Unit Awards
Results Clinical Trials Not Favorable Unable Obtain Regulatory Results Conference Call
Results Conference Call Information Results Operations
Results Operations Financial Condition Revenue Dependent Sale Zadaxin Foreign Countries Particularly China
Revenue Recognition Revolving Advances
Risk Factors Risk Securities Class Action Litigation
Royalties Rp101
Rp101 Cancer Rp101 Late-stage Pancreatic Cancer Patients
Sales Common Stock Officers Directors Affect Price Sales Marketing
Sales Marketing Business Unit China Sales Marketing Expenses
Sales Thymalfasin Fluctuate Due Seasonality Product Orders Not Sales Zadaxin Fluctuate Due Seasonality Product Orders Not
Scale-up Scale-up Costs
Schedule Schedule Minimum Ebit
Schedule Minimum Revenue Schedule Valuation Qualifying Accounts
Sciclone Sciclone Announces Corporate Restructuring Workforce Reduction
Sciclone Announces Departure Chief Financial Officer Sciclone Bio Ceo Investor Meeting
Sciclone Chinas Established Business Sciclone Pharmaceuticals Inc
Sciclones Development Obligations Sciclones Established Sales Marketing Organization
Sciclones Lead Product Zadaxin Sciclones Lead Product Zadaxin Thymalfasin
Scv-07 Scv-07 Infectious Diseases Oncology
Scv-07 Viral Infectious Diseases Securities Authorized Issuance Equity Compensation Plans
Securities Exchange Act 1934 Securities Registered Pursuant Act
Segment Information Selected Balance Sheet Data
Settlements Regarding Claims Relating Japanese Clinical Trials Not Severance Obligation
Shares Represented Hereby Shall Voted Specified Specification Such Shares Subject Plan
Shipment Delivery Shipping Handling Costs
Short Term Investments Subject Certain Risks Materially Adversely Sigma-tau
Sigma-tau Designees Been Appointed Sciclone Board Sigma-tau Finanziaria Spa
Sigma-tau Group Signature
Signature Page Follow Signature Page Follows
Signatures Significant Geographic Information
Silicon Valley Bank Solicitation Proxies
Solicited Board Directors Special Deduction Limit
Special Regarding Forward-looking Statements Specification Licensed Product
Standard Forms Award Agreement Standard Forms Option Agreement
Standstill Restrictions Stock Appreciation Rights
Stock Award Plans Stock Awards
Stock Based Compensation Stock Option Valuation
Stock Options Stock Performance Graph
Stock Price Continue Experience Volatility Not Comply Certain Stock Price Volatile Investment Suffer Decline Value
Stock Price Volatile Investment Suffer Decline Value Not Stock-based Compensation
Stockholder Proposals Stockholder Rights Agreement
Stockholders Stockholders Equity
Storage Shipping Instructions Strategy
Subject Currency Exchange Rate Fluctuations Adversely Affect Financial Subject Product Liability Lawsuits Insurance Inadequate Cover Damages
Submission Matters Vote Security Holders Subsequent Event
Substantial Sales Equity Subsidiaries Stock Exercise Conversion Options Substantial Sales Stock Equity Subsidiaries Exercise Conversion Options
Substantial Sales Stock Exercise Conversion Options Convertible Securities Summary Compensation Table
Summary Significant Accounting Policies Supply Licensed Product Manufacture Api
Table Contents Table Ntents
Target Stock Price Option Tax Considerations
Tax Withholding Term
Term Termination Term Termination Breach
Termination Amendment Plan Terms Conditions Options
Third-party Reimbursement Third-party Reimbursement Not Available Patients Cannot Otherwise Pay
Thymalfasin Advanced-stage Malignant Melanoma Thymalfasin Triple Therapy Hcv
Thymalfasin Works Melanoma Title Class
Total Revenues Transfer Rp101 Assets
Transition Period Triple Therapy Pilot Study Results
Ubs Bank Usa Unable Commercialize Zadaxin Various Markets Multiple Indications Particularly
Unable Comply Environmental Other Laws Regulations Business Harmed Unable Manage Key Personnel Attract Retain Additional Highly
Undersigned Represents Warrants Borrowing Base Certificate True Complete United States
Upcoming Milestones Voting Proxies
Voting Securities Warranties
Washington 20549 What Compensation Program Designed Reward
Whether Not Plan Attend Meeting Person Urged Promptly Witness Whereof Parties Hereto Caused Agreement Executed Effective
Witness Whereof Undersigned Executed Officers Certificate 2008 Borrowers Year-end 2008
Year-end Results 2009 Zadaxin Advanced-stage Malignant Melanoma
Zadaxin Agreement Zadaxin Hepatitis
Zadaxin Hepatocellular Carcinoma Zadaxin Thymalfasin Advanced-stage Malignant Melanoma
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki